Loading...
Loading...
Among the 4 tracked institutional investors we monitor, PMCB (PHARMACYTE BIOTECH INC) is held with a combined value of $437.68K across 651,167 shares. The largest holder is CITADEL ADVISORS LLC with a position worth $345.84K (0.00% of their portfolio). VANGUARD GROUP INC opened a new position in the most recent quarter. 1 fund increased its holdings. 1 fund reduced its position.
Total Institutional Value
$437.68K
Total Shares Held
651,167
Institutional Holders
4
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $345.84K | 0.00% | +25.0% |
| 2 | VANGUARD GROUP INC | $54.24K | 0.00% | New |
| 3 | RENAISSANCE TECHNOLOGIES LLC | $37.59K | 0.00% | -39.9% |
| 4 | BlackRock, Inc. | $1 | 0.00% | - |
As of the latest SEC 13F filings, CITADEL ADVISORS LLC is the largest institutional holder of PMCB with a position worth $345.84K, representing 0.00% of their portfolio. In total, 4 institutional investors hold PMCB with a combined value of $437.68K.
In the most recent quarter, 1 fund opened a new position in PMCB. Additionally, 1 increased their holdings and 1 reduced their positions.
Institutional investors hold $437.68K worth of PMCB stock across 4 positions. The largest institutional holder is CITADEL ADVISORS LLC with $345.84K in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For PMCB, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their PMCB positions.